TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-23.26M |
| Operating Margin | 0.00% |
| Return on Equity | -52.10% |
| Return on Assets | -17.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 6.68 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 950,300 |
| Float | 865,760 |
| % Insiders | 8.90% |
| % Institutions | 7.63% |
Volatility is currently expanding
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript
TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics. BOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced further results of the Phase 1a dose escalation clinical trial.
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode's lead therapeutic candidate, TTX‑MC138, in patients with circulating tumor DNA (ctDNA) positive colorectal cancer following curative‑intent therapy.
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a co-founder of TransCode Therapeutics and globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics.
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.
